Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured hiv patients in the United States

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Sax, Paul E ^a   Meyers, Juliana L ^b   Mugavero, Michael ^c   Davis, Keith L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; RISK ASSESSMENT; TREATMENT DURATION; UNITED STATES; AGED; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RISK; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; REGRESSION ANALYSIS; RISK; TREATMENT OUTCOME; UNITED STATES;

EID: 84857529579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031591     Document Type: Article

References (29)

1. Fielden SJ, Rusch ML, Yip B, Wood E, Shannon K, et al. (2008) Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naïve patients started on HAART. J Int Assoc Physicians AIDS Care 7: 238-244.
2. Kitahata MM, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, et al. (2004) Pharmacy-based assessment of adherence to HAART predicts virological and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS 15: 803-810.
3. Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al. (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×109 cells/L. Ann Intern Med 139: 810-816.
4. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. (2001) Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15: 1181-1183.
5. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services (2009) Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGI.pdf. Accessed 2011 Feb 4.
7. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, et al. (2010) Recommendations of the IAS-USA Panel. JAMA 304: 321-333.
8. DeJesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, et al. (2009) Simplification of antiretroviral therapy to a single tablet regimen consisting of efavirenz, emtricitabine and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 51: 163-174.
9. Hodder SL, Mounzer K, DeJesus E, Ebrahimi R, Grimm K, et al. (2010) Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single tablet regimen of efavirenz, emtricitabine and tenofovir DF. AIDS Patient Care STDs 24: 115-125.
10. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, et al. (2010) One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 4: 115-125.
11. Bangsberg DR, Ragland K, Monk A, Deeks SG, (2010) A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 24: 2835-2840.
12. Charlson ME, Pompei P, Ales KL, McKenzie CR, (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40: 373-383.
13. Andrade SE, Kristijan KH, Frech F, Chan K, (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15: 565-574.
14. Legorreta A, Yu A, Chernicoff H, Gilmore A, Jordan J, et al. (2005) Adherence to combined lamivudine+zidovudine versus individual components: a community-based retrospective Medicaid claims analysis. AIDS Care 17: 938-948.
15. Parienti J-J, Bangsberg DR, Verdon R, Gardner EM, (2009) Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 48: 484-488.
16. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, et al. (2001) Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report an electronic monitoring. Clin Infect Dis 33: 1417-1423.
17. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14: 357-366.
18. Andrews L, Friedland G, (2000) Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. Infect Dis Clin North Am 14: 901-928.
19. Bangsberg DR, (2006) Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43: 939-941.
20. Cohen CJ, Colson AE, Shebie-Hall AG, McLaughlin KA, Morse GD, (2007) Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials 8: 19-23.
21. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, et al. (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25: F7-F12.
22. Cohen C, Molina J-M, Cahn P, Clotet B, Supparatpinyo K, et al. (2010) Pooled 48 week efficacy and safety results from ECHO and THRIVE, two double-blind, randomized, phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients. Abstract presented at the World AIDS Conference; Vienna, Austria. 18-23 July. Abstract No. THLBB206.
23. Bangsberg DR, Ragland K, Monk A, Deeks SG, (2010) A one-pill, once-daily, fixed-dose combination (FDC) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (EFV/FTC/TDF) regimen is associated with higher unannounced pill count adherence than non-one pill, once-daily. Abstract presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA. 16-19 February. Abstract No. 510.
24. Fielden SJ, Rusch ML, Yip B, Wood E, Shannon K, et al. (2008) Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naïve patients started on HAART. J Int Assoc Physicians AIDS Care 7: 238-244.
25. Juday T, Gupta S, Grimm K, Wagner S, Kim E, (2011) Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials 12: 71-78.
26. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, et al. (2011) Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis 52: 493-506.
27. Daar ES, Tierney C, Fischi MA, Sax PE, Mollan K, et al. (2011) Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 154: 445-456.
28. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106.
29. Hellinger FJ, Encinosa WE, (2010) The cost and incidence of prescribing errors among privately insured HIV patients. Pharmacoeconomics 28: 23-34.